US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
58 deals · US$48bndisclosed · Life Sciences · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Dec 2025 | Generation Bio Co. | – | XRA 7 Corp. | Acquisition | Announced | – | Biotech+1 | TD Securities (sell-side)WilmerHale (sell-side)Gibson Dunn (buy-side) |
| Dec 2025 | Freenome Holdings | – | Perceptive Capital Solutions Corp | Merger | Completed | 725.0 | Diagnostics+2 | TD Securities (sell-side)Guggenheim Securities (sell-side)BTIG (sell-side)Goodwin (sell-side)Greenberg Traurig (sell-side)Richards, Layton & Finger (sell-side)H.C. Wainwright & Co. (sell-side)Jefferies (buy-side)Leerink Partners (buy-side)Cooley (buy-side)Ropes & Gray (buy-side)Maples Group (buy-side)Ogier (buy-side)Scalar (buy-side) |
| Oct 2025 | SWK Holdings | – | Runway Growth Finance Corp. | Acquisition | Completed | 249.0 | Financial Services+1 | Keefe, Bruyette & Woods (sell-side)Goodwin (sell-side)Kroll (sell-side)Simpson Thacher & Bartlett (buy-side)Dechert (buy-side) |
| Jul 2025 | BD Biosciences & Diagnostic Solutions business | Becton, Dickinson and Company | Waters | Asset sale | Completed | 18,800.0 | Life Sciences+2 | Citi (sell-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Barclays (buy-side)Kirkland & Ellis (buy-side) |
| Feb 2025 | Mayne Pharma Group | – | Cosette Pharmaceuticals | Scheme | Withdrawn | 417.9 | Healthcare+1 | Jefferies (sell-side)Gilbert + Tobin (sell-side)Arnold & Porter (sell-side)Davis Wright Tremaine (sell-side)EY (sell-side)Deloitte (sell-side)Santander (buy-side)UBS (buy-side)Corrs Chambers Westgarth (buy-side)Ropes & Gray (buy-side) |
| Feb 2025 | AdvanCell | – | SV Health Investors | Stake | Completed | – | Healthcare+1 | Johnson Winter Slattery (buy-side)Honigman (buy-side) |
| Jan 2025 | ImaginAb therapeutic candidates, biologics technology platform and research facility | ImaginAb | Telix Pharmaceuticals | Asset sale | Completed | 45.0 | Healthcare+1 | Jefferies (sell-side)Stifel (sell-side) |
| Apr 2024 | Model N | – | Vista Equity Partners | Acquisition | Completed | 1,250.0 | Vertical SaaS+1 | Jefferies (sell-side)Fenwick & West (sell-side)Kirkland & Ellis (buy-side)William Blair (buy-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built